Latest Breaking News On - தடுப்பு மருந்துகள் நாள் - Page 3 : comparemela.com

(Moderna) Moderna, sitting on a powder keg of cash after launching a COVID-19 vaccine that s being distributed around the world, is not going to be resting on its laurels anytime soon. New interim phase 1 data for the biotech s respiratory syncytial virus, or RSV, vaccine candidate called mRNA-1345 showed the treatment was well tolerated in younger adults and increased neutralizing antibodies in patients with the virus. The candidate is based on the same mRNA technology that brought the COVID-19 vaccine to the world. The Cambridge, Massachusetts-based biotechnology company has 14 different mRNA candidates launched into clinical trials already with plans to further invest in the mRNA platform. Moderna is hosting its second annual Vaccines Day on April 14.

United kingdomUnited statesBiovitrum synagisJacqueline millerVaccines dayBig pharmaSwedish orphan biovitrumCorona virusRsv virusModerna therapeuticsBusiness developmentCovid 19Combination therapyஒன்றுபட்டது கிஂக்டம்ஒன்றுபட்டது மாநிலங்களில்ஜாக்குலின் மில்லர்